Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer

Triple-negative breast cancer (TNBC) constitutes a very aggressive type of breast cancer with few options of cytotoxic chemotherapy available for them. A chemotherapy regimen comprising of doxorubicin hydrochloride and cyclophosphamide, followed by paclitaxel, known as AC-T, is approved for usage as...

Descripción completa

Detalles Bibliográficos
Autores principales: Guido, Bruna Cândido, Brandão, Douglas Cardoso, Barbosa, Ana Luisa Augusto, Vianna, Monique Jacob Xavier, Faro, Lucas, Ramos, Luciana Machado, Nihi, Fabíola, de Castro, Márcio Botelho, Neto, Brenno A.D., Corrêa, José Raimundo, Báo, Sônia Nair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448514/
https://www.ncbi.nlm.nih.gov/pubmed/34548908
http://dx.doi.org/10.18632/oncotarget.28068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448514/
https://www.ncbi.nlm.nih.gov/pubmed/34548908
http://dx.doi.org/10.18632/oncotarget.28068

Ejemplares similares